Article
Oncology
Christina I. Tsien, Stephanie L. Pugh, Adam P. Dicker, Jeffrey J. Raizer, Martha M. Matuszak, Enrico C. Lallana, Jiayi Huang, Ozer Algan, Nimisha Deb, Lorraine Portelance, John L. Villano, John T. Hamm, Kevin S. Oh, Arif N. Ali, Michelle M. Kim, Scott M. Lindhorst, Minesh P. Mehta
Summary: This study evaluated whether reirradiation (re-RT) and concurrent bevacizumab (BEV) improve overall survival (OS) and/or progression-free survival (PFS) compared to BEV alone in recurrent glioblastoma (GBM). The results showed that the combination of re-RT and BEV significantly improved PFS, but had no difference in OS.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Henry S. Friedman, Michael D. Prados, Patrick Y. Wen, Tom Mikkelsen, David Schiff, Lauren E. Abrey, W. K. Alfred Yung, Nina Paleologos, Martin K. Nicholas, Randy Jensen, James Vredenburgh, Jane Huang, Maoxia Zheng, Timothy Cloughesy
Summary: This study evaluated the efficacy of bevacizumab, alone or in combination with irinotecan, in recurrent glioblastoma patients. The results showed that bevacizumab, either alone or in combination, was well tolerated and active in treating recurrent glioblastoma.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Katja Werlenius, Sara Kinhult, Tora Skeidsvoll Solheim, Henriette Magelssen, David Loefgren, Munila Mudaisi, Sofia Hylin, Jiri Bartek, Michael Strandeus, Magnus Lindskog, Havyan Bahroz Rashid, Louise Carstam, Sasha Gulati, Ole Solheim, Jiri Bartek, Oyvind Salvesen, Asgeir Store Jakola
Summary: In patients with recurrent glioblastoma, the addition of disulfiram and copper to chemotherapy resulted in significantly increased toxic effects, but no significant difference in survival, according to this multicenter, open-label, randomized phase II/III clinical trial. These findings suggest that disulfiram and copper is without benefit in patients with recurrent glioblastoma.
Article
Biochemistry & Molecular Biology
Farshad Nassiri, Vikas Patil, Leeor S. Yefet, Olivia Singh, Jeff Liu, Rachel M. A. Dang, Takafumi N. Yamaguchi, Mariza Daras, Timothy F. Cloughesy, Howard Colman, Priya U. Kumthekar, Clark C. Chen, Robert Aiken, Morris D. Groves, Shirley S. Ong, Rohan Ramakrishna, Michael A. Vogelbaum, Simon Khagi, Thomas Kaley, Jason M. Melear, David M. Peereboom, Analiz Rodriguez, Maxim Yankelevich, Suresh G. Nair, Vinay K. Puduvalli, Kenneth Aldape, Andrew Gao, Alvaro Lopez-Janeiro, Carlos E. de Andrea, Marta M. Alonso, Paul Boutros, Joan Robbins, Warren P. Mason, Adam M. Sonabend, Roger Stupp, Juan Fueyo, Candelaria Gomez-Manzano, Frederick F. Lang, Gelareh Zadeh
Summary: Immune-mediated anti-tumoral responses, elicited by oncolytic viruses and augmented with checkpoint inhibition, were evaluated in a multicenter phase 1/2 study for the treatment of recurrent glioblastoma. The combination of intratumoral DNX-2401 followed by intravenous pembrolizumab showed notable survival benefit with an objective response rate of 10.4% and overall survival at 12 months of 52.7%. Exploratory analyses suggested potential predictors of treatment response and resistance. Overall, this combination therapy demonstrated promising results in select patients with glioblastoma.
Article
Oncology
Qin Xu, Junjie Wang, Yang Sun, Yibin Lin, Jing Liu, Yanhong Zhuo, Zhangzhou Huang, Songhua Huang, Ying Chen, Li Chen, Meifang Ke, Li Li, Zirong Li, Junping Pan, Yanwen Song, Rongqiang Liu, Chuanben Chen
Summary: This study investigated the efficacy and safety of sintilimab plus anlotinib as second-line or later therapy for PD-L1-positive advanced cervical cancer patients. The results showed a high objective response rate and disease control rate of sintilimab plus anlotinib in these patients, along with a certain proportion of treatment-related adverse events.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Motoo Nagane, Koichi Ichimura, Ritsuko Onuki, Daichi Narushima, Mai Honda-Kitahara, Kaishi Satomi, Arata Tomiyama, Yasuhito Arai, Tatsuhiro Shibata, Yoshitaka Narita, Takeo Uzuka, Hideo Nakamura, Mitsutoshi Nakada, Yoshiki Arakawa, Takanori Ohnishi, Akitake Mukasa, Shota Tanaka, Toshihiko Wakabayashi, Tomokazu Aoki, Shigeki Aoki, Soichiro Shibui, Masao Matsutani, Keisuke Ishizawa, Hideaki Yokoo, Hiroyoshi Suzuki, Satoshi Morita, Mamoru Kato, Ryo Nishikawa
Summary: This study evaluated the efficacy and safety of bevacizumab in Japanese patients with newly diagnosed glioblastoma and identified an expression classifier that may predict patient prognosis.
Article
Oncology
Qingsheng Xu, Kaiyuan Huang, Xiangqi Meng, Yuxiang Weng, Luyuan Zhang, Linghao Bu, Xiujue Zheng, Jinquan Cai, Renya Zhan, Qun Chen
Summary: The combination of anlotinib and temozolomide showed high efficacy and tolerability in treating recurrent GBM, with a good tumor response rate and disease control rate. This treatment regimen may contribute to an increase in progression-free survival and overall survival in patients with recurrent GBM.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Adam S. Levy, Mark Krailo, Susan Chi, Doojduen Villaluna, Linda Springer, Chris Williams-Hughes, Maryam Fouladi, Amar Gajjar
Summary: The study compared the overall survival and event-free survival of different treatment regimens for recurrent MB in children. The addition of bevacizumab significantly reduced the risk of death and was relatively well tolerated. This suggests that the three-drug combination is worthy of further investigation.
PEDIATRIC BLOOD & CANCER
(2021)
Article
Oncology
Shukui Qin, Zhendong Chen, Weijia Fang, Zhenggang Ren, Ruocai Xu, Baek-Yeol Ryoo, Zhiqiang Meng, Yuxian Bai, Xiaoming Chen, Xiufeng Liu, Juxiang Xiao, Gwo Fuang Ho, Yimin Mao, Xin Wang, Jieer Ying, Jianfeng Li, Wenyan Zhong, Yu Zhou, Abby B. Siegel, Chunyi Hao
Summary: Pembrolizumab significantly prolonged overall survival and progression-free survival in previously treated advanced hepatocellular carcinoma patients from Asia, with a higher objective response rate compared to placebo.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
B. Liu, L. Liu, J. Ran, N. Xie, J. Li, H. Xiao, X. Yang, C. Tian, H. Wu, J. Lu, J. Gao, X. Hu, M. Cao, Z. Shui, Z. -y. Hu, Q. Ouyang
Summary: This study compared the efficacy and safety of eribulin plus anlotinib versus eribulin monotherapy in patients with locally recurrent or metastatic breast cancer. The results showed that the combination therapy significantly improved progression-free survival and had higher rates of local control and objective response compared to eribulin alone, making it a viable treatment option for HER2-negative locally advanced or metastatic breast cancer.
Article
Oncology
Nitya Raj, Jennifer A. Chan, Stephanie J. Wang, Rahul R. Aggarwal, Susan Calabrese, April DeMore, Lawrence Fong, Jennifer Grabowsky, Thomas A. Hope, Kanti Pallav Kolli, Claire K. Mulvey, Pamela N. Munster, Kimberly Perez, Sippy Punn, Diane Reidy-Lagunes, Sofia Von Fedak, Li Zhang, Emily K. Bergsland
Summary: Single-agent immune checkpoint inhibitor therapy has shown limited effectiveness against EP-PDNECs, and the efficacy of combination therapy with chemotherapy is still being investigated. This study evaluated the effectiveness of pembrolizumab alone and pembrolizumab plus chemotherapy in patients with advanced EP-PDNECs.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Lei She, Lin Su, Chao Liu
Summary: The purpose of this study was to evaluate the safety, tolerability, and efficacy of a combination of BEV and re-RT for the treatment of rGBM. The results showed that this combination therapy was safe, tolerable, and effective in rGBM patients. Additionally, gross total resection prior to re-RT and selective concurrent temozolomide further improved patient PFS and OS.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Gang Yang, Yu Fang, Ming Zhou, Wei Li, Dapeng Dong, Jing Chen, Yong Da, Kunpeng Wang, Xinru Li, Xiaoyan Zhang, Tonghui Ma, Ge Shen
Summary: We report a case of recurrent glioblastoma with lung metastasis, treated with a combination therapy of bevacizumab and pembrolizumab, which resulted in a longer overall survival. Additionally, this is the first use of bevacizumab plus pembrolizumab as a maintenance treatment for glioblastoma.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Wei Wei, Xiaohua Ban, Fan Yang, Jibin Li, Xiaqin Cheng, Rong Zhang, Xin Huang, Yongwen Huang, Qiaqia Li, Ya Qiu, Min Zheng, Xiaofeng Zhu, Jundong Li
Summary: This study investigated the therapeutic effect of anlotinib combined with monoclonal antibody intravenous injection on Chinese patients with endometrial cancer. The results showed that this combination treatment had a good efficacy and tolerable toxicity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Medicine, Research & Experimental
Ruijian Li, Weiyi Li, Fang Zhang, Shanshan Li
Summary: A meta-analysis of two randomized controlled trials (RCTs) showed that the combination of bevacizumab and erlotinib can significantly prolong progression-free survival (PFS) but not overall survival (OS) in advanced EGFR-mutant non-small cell lung cancer patients. However, for patients with brain metastasis at baseline, the combination therapy demonstrated better PFS and a tendency to prolong OS.
EUROPEAN JOURNAL OF MEDICAL RESEARCH
(2023)
Article
Engineering, Electrical & Electronic
Anubhav Kumar, Asok De, R. K. Jain
Summary: This study presents a two-element textile antenna with high isolation and polarization diversity, suitable for 5G communications, wearable technology, and biomedical cancer detection applications. The use of flexible material and an orthogonally placed microstrip-feed radiator antenna enables polarization diversity, while high isolation and low correlation are achieved through a defected ground. The antenna demonstrates circular polarization and performs well in terms of impedance bandwidth, isolation, envelope correlation coefficient, and channel capacity loss.
INTERNATIONAL JOURNAL OF MICROWAVE AND WIRELESS TECHNOLOGIES
(2023)
Review
Oncology
Sonia A. Patel, Monique B. Nilsson, Xiuning Le, Tina Cascone, Rakesh K. Jain, John V. V. Heymach
Summary: Angiogenesis is an important mechanism used by solid tumors to recruit blood vessels for growth. Drugs targeting the VEGF/VEGFR pathway have been approved for various solid tumor types, but the survival benefits have been limited. However, these drugs have the potential to reprogram the tumor microenvironment, leading to the approval of combinations with immune checkpoint blockers. Understanding the mechanisms of response and resistance to these drugs is crucial for developing more effective therapeutic approaches.
CLINICAL CANCER RESEARCH
(2023)
Article
Gastroenterology & Hepatology
Bolni Marius Nagalo, Yumei Zhou, Emilien J. Loeuillard, Chelsae Dumbauld, Oumar Barro, Alexander T. Baker, Mansi Arora, James M. Bogenberger, Natalie Meurice, Joachim Petit, Pedro Luiz Serrano Uson, Faaiq Asiam, Elizabeth Raupach, Musa Gabere, Alexei Basnakian, Camila C. Simoes, Martin J. Cannon, Steven R. Post, Kenneth Buetow, Jean Christopher Chamcheu, Michael T. Barrett, Dan G. Duda, Bertram Jacobs, Richard Vile, Michael A. Barry, Lewis R. Roberts, Sumera Llyas, Mitesh J. Borad
Summary: This study demonstrates that wild-type Morreton virus has potential therapeutic effects on cholangiocarcinoma and hepatocellular carcinoma in vitro models. It can induce immune responses and lead to tumor regression. These findings support further development and clinical translation of Morreton virus as an oncolytic virotherapy platform.
Article
Gastroenterology & Hepatology
Shuling Chen, Cheng Huang, Guanrui Liao, Huichuan Sun, Yubin Xie, Changyi Liao, Jianping Wang, Minghui He, Huanjing Hu, Zihao Dai, Xiaoxue Ren, Xuezhen Zeng, Zhilong Lin, Guo-Pei Zhang, Wenxuan Xie, Shunli Shen, Shaoqiang Li, Sui Peng, Dong-Ming Kuang, Qiang Zhao, Dan G. Duda, Ming Kuang
Summary: Analyzing the single-cell immune ecosystems in recurrent hepatocellular carcinoma (HCC) can aid in the development of effective immunotherapies. The study identified de novo and true recurrences in HCC samples and found distinct immune characteristics in the tumor immune microenvironment (TIME) of these recurrences. The findings suggest the need for different immunotherapy strategies based on the type of HCC recurrence and the specific TIME.
Article
Oncology
Shawn L. Hervey-Jumper, Yalan Zhang, Joanna J. Phillips, Ramin A. Morshed, Jacob S. Young, Lucie McCoy, Marisa Lafontaine, Tracy Luks, Simon Ammanuel, Sofia Kakaizada, Andrew Egladyous, Andrew Gogos, Javier Villanueva-Meyer, Anny Shai, Gayathri Warrier, Terri Rice, Jason Crane, Margaret Wrensch, John K. Wiencke, Mariza Daras, Nancy Ann Oberheim Bush, Jennie W. Taylor, Nicholas Butowski, Jennifer Clarke, Susan Chang, Edward Chang, Manish Aghi, Philip Theodosopoulos, Michael McDermott, Asgeir S. Jakola, Vasileios K. Kavouridis, Noah Nawabi, Ole Solheim, Timothy Smith, Mitchel S. Berger, Annette M. Molinaro
Summary: In patients with diffuse low-grade glioma, the extent of surgical tumor resection has a controversial role in prognosis, but a randomized clinical trial is not feasible to determine different levels of resection.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Yves Boucher, Jessica M. Posada, Sonu Subudhi, Ashwin S. Kumar, Spencer R. Rosario, Liqun Gu, Heena Kumra, Mari Mino-Kenudson, Nilesh P. Talele, Dan G. Duda, Dai Fukumura, Jennifer Y. Wo, Jeffrey W. Clark, David P. Ryan, Carlos Fernandez-Del Castillo, Theodore S. Hong, Mikael J. Pittet, Rakesh K. Jain
Summary: In this study, we found that adding losartan (LOS) to FOLFIRINOX (FFX) chemotherapy followed by chemoradiation (CRT) in patients with locally advanced pancreatic cancer (LAPC) resulted in a 61% R0 surgical resection rate. By evaluating the effects of neoadjuvant LOS on the tumor microenvironment, we identified potential mechanisms of benefit. The results showed that LOS+FFX+CRT reduced the expression of immunosuppression and pro-invasion genes and was associated with improved overall survival (OS).
CLINICAL CANCER RESEARCH
(2023)
Article
Engineering, Electrical & Electronic
Anubhav Kumar, Asok De, R. K. Jain
Summary: In this paper, a compact two-port antenna design is proposed, featuring an open-ended slot loaded with shorting pins and a T-shaped stub. The antenna radiators, shaped like beaks, enhance bandwidth and electrical length. Dual-operating bands are achieved by the two inverted L-shaped open-ended slots, which create an effective capacitance and inductance. The T-shaped stub improves impedance matching and electrical height to ground, while the combination of the T-shape and open-ended slots provides a dual-band response and up to 8 dB of isolation improvement. Shorting pins connected to the ground exhibit inductive behavior, resulting in isolation improvements of up to 6 dB and 4 dB for the low- and high-frequency bands. The two-port antenna demonstrates over 20 dB of isolation with a mere 2 mm edge-to-edge distance. Operating in the frequency ranges of 4.1 GHz to 4.6 GHz and 5.55 GHz to 6 GHz, the antenna's size of 32 mm x 26.5 mm makes it suitable for 5G and WLAN/ISM applications.
IETE JOURNAL OF RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Ingo K. Mellinghoff, Min Lu, Patrick Y. Wen, Jennie W. Taylor, Elizabeth A. Maher, Isabel Arrillaga-Romany, Katherine B. Peters, Benjamin M. Ellingson, Marc K. Rosenblum, Saewon Chun, Kha Le, Ania Tassinari, Sung Choe, Youssef Toubouti, Steven Schoenfeld, Shuchi S. Pandya, Islam Hassan, Lori Steelman, Jennifer L. Clarke, Timothy F. Cloughesy
Summary: In a pilot perioperative randomized clinical trial, the dual IDH1/IDH2 inhibitor vorasidenib was found to have better brain permeability and target engagement than ivosidenib in patients with IDH1-mutant glioma. Both agents showed significant reduction in tumor 2-HG concentrations, with vorasidenib demonstrating more consistent suppression. Exploratory analyses revealed additional positive effects of 2-HG reduction. Vorasidenib was selected for further testing in phase 3 trials. This study was funded by Agios Pharmaceuticals, Inc. and Servier Pharmaceuticals LLC.
Article
Medicine, General & Internal
Ingo K. Mellinghoff, Martin J. van den Bent, Deborah T. Blumenthal, Mehdi Touat, Katherine B. Peters, Jennifer Clarke, Joe Mendez, Shlomit Yust-Katz, Liam Welsh, Warren P. Mason, Francois Ducray, Yoshie Umemura, Burt Nabors, Matthias Holdhoff, Andreas F. Hottinger, Yoshiki Arakawa, Juan M. Sepulveda, Wolfgang Wick, Riccardo Soffietti, James R. Perry, Pierre Giglio, Macarena de la Fuente, Elizabeth A. Maher, Steven Schoenfeld, Dan Zhao, Shuchi S. Pandya, Lori Steelman, Islam Hassan, Patrick Y. Wen, Timothy F. Cloughesy
Summary: In a phase 3 trial, vorasidenib showed significant improvement in progression-free survival and delay in the time to the next intervention for patients with grade 2 IDH-mutant glioma.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Xinyue Dong, Jun Ren, Zohreh Amoozgar, Somin Lee, Meenal Datta, Sylvie Roberge, Mark Duquette, Dai Fukumura, Rakesh K. Jain
Summary: Chimeric antigen receptor (CAR)-T cells have limited efficacy in treating glioblastoma (GBM) and other solid tumors due to the immunosuppressive tumor microenvironment (TME). Previous studies have shown that blocking vascular endothelial growth factor (VEGF) signaling can improve tumor vessel normalization and enhance the delivery of CD8+ T cells for effective immunotherapy. In this study, the researchers tested the hypothesis that anti-VEGF therapy can improve the delivery and efficacy of CAR-T cells in mice with GBM tumors, and found that it indeed enhanced CAR-T cell infiltration, delayed tumor growth, and prolonged survival.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Eleni Gkika, Elke Firat, Sonja Adebahr, Erika Graf, Ilinca Popp, Gianluca Radicioni, Simon S. Lo, Ursula Nestle, Nils H. Nicolay, Gabriele Niedermann, Dan G. Duda, Anca-L. Grosu
Summary: We conducted a prospective study to investigate the changes in circulating immune cells after stereotactic body radiotherapy (SBRT) in early-stage NSCLC patients. We found no significant increase in CD8(+) cytotoxic T lymphocytes at the first follow-up, but observed a significant expansion in Ki-67(+)CD8(+) and Ki-67(+)CD4(+) T-cell fractions in patients receiving 10 Gy or less per fraction. Our findings suggest that SBRT can induce immediate expansion of circulating effector T-cells.
NPJ PRECISION ONCOLOGY
(2023)
Correction
Biochemistry & Molecular Biology
Ingo K. Mellinghoff, Min Lu, Patrick Y. Wen, Jennie W. Taylor, Elizabeth A. Maher, Isabel Arrillaga-Romany, Katherine B. Peters, Benjamin M. Ellingson, Marc K. Rosenblum, Saewon Chun, Kha Le, Ania Tassinari, Sung Choe, Youssef Toubouti, Steven Schoenfeld, Shuchi S. Pandya, Islam Hassan, Lori Steelman, Jennifer L. Clarke, Timothy F. Cloughesy
Article
Oncology
Atsuro Saijo, Hirokazu Ogino, Nicholas A. Butowski, Meghan R. Tedesco, David Gibson, Payal B. Watchmaker, Kaori Okada, Albert S. Wang, Anny Shai, Andres M. Salazar, Annette M. Molinaro, Jane E. Rabbitt, Maryam Shahin, Arie Perry, Jennifer L. Clarke, Jennie W. Taylor, Mariza Daras, Nancy Ann Oberheim Bush, Shawn L. Hervey-Jumper, Joanna J. Phillips, Susan M. Chang, Norbert Hilf, Andrea Mayer-Mokler, Tibor Keler, Mitchel S. Berger, Hideho Okada
Summary: The combinational immunotherapy with multipeptide IMA950 vaccine and varlilumab induction demonstrated vaccine-reactive T-cell expansion in the peripheral blood but without a detectable response in the tumor microenvironment.
Review
Oncology
Betul Gok Yavuz, Saumil Datar, Shadi Chamseddine, Yehia I. Mohamed, Michael LaPelusa, Sunyoung S. Lee, Zishuo Ian Hu, Eugene J. Koay, Hop S. Tran Cao, Prasun Kumar Jalal, Carrie Daniel-MacDougall, Manal Hassan, Dan G. Duda, Hesham M. Amin, Ahmed O. Kaseb
Summary: Hepatocellular carcinoma (HCC) is the most common type of liver cancer, and the gut microbiome may play a role in its detection and treatment, particularly in immunotherapy. This review examines the gut microbiome's potential as a biomarker for HCC and its impact on immunotherapy. It also discusses the bidirectional interactions between the gut and liver and the role of gut microbiota in cancer treatment.
Meeting Abstract
Oncology
Rakesh K. Jain